Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTVA
2751
MetaVia Inc
MTVA
$7.59M
| $526K | ﹤0.01% |
+1
| New | +$725K |
|
|
ARCW
2752
DELISTED
ARC Group Worldwide, Inc
ARCW
| $525K | ﹤0.01% |
186,300
+4,980
| +3% | +$17.5K |
|
2753
VanEck Gold Miners ETF
GDX
$26.9B
| $523K | ﹤0.01% |
23,700
-40,500
| -63% | -$921K |
|
|
ASBB
2754
DELISTED
ASB Bancorp Inc
ASBB
| $523K | ﹤0.01% |
+11,900
| New | +$480K |
|
|
FGNX
2755
FG Nexus Inc
FGNX
$40.2M
| $522K | ﹤0.01% |
523
+101
| +24% | +$96.7K |
|
|
GFED
2756
DELISTED
Guaranty Federal Bancshares In
GFED
| $522K | ﹤0.01% |
25,800
+400
| +2% | +$7.98K |
|
|
HWCC
2757
DELISTED
Houston Wire & Cable Company
HWCC
| $521K | ﹤0.01% |
100,100
+2,700
| +3% | +$16.9K |
|
2758
Community Bank
CBU
$3.43B
| $515K | ﹤0.01% |
9,240
-66,389
| -88% | -$3.67M |
|
2759
First Bank
FRBA
$471M
| $515K | ﹤0.01% |
44,200
-9,400
| -18% | -$115K |
|
|
AATC
2760
DELISTED
Autoscope Technologies Corporation Common Stock
AATC
| $515K | ﹤0.01% |
143,100
-12,400
| -8% | -$40.1K |
|
|
MBFI
2761
DELISTED
MB Financial Corp
MBFI
| $515K | ﹤0.01% |
11,700
-99,693
| -89% | -$4.25M |
|
2762
Distribution Solutions Group
DSGR
$1.61B
| $514K | ﹤0.01% |
46,400
-20,200
| -30% | -$213K |
|
2763
Suncor Energy
SU
$74.7B
| $514K | ﹤0.01% |
17,600
-240,940
| -93% | -$7.41M |
|
2764
AZZ Inc
AZZ
$4.55B
| $508K | ﹤0.01% |
+9,100
| New | +$517K |
|
2765
FS Bancorp
FSBW
$325M
| $508K | ﹤0.01% |
23,200
+5,400
| +30% | +$116K |
|
|
AXE
2766
DELISTED
Anixter International Inc
AXE
| $508K | ﹤0.01% |
+6,500
| New | +$508K |
|
2767
LGL Group
LGL
$93.3M
| $502K | ﹤0.01% |
276,073
+73,195
| +36% | +$133K |
|
2768
Norwood Financial Corp
NWFL
$376M
| $499K | ﹤0.01% |
+17,700
| New | +$467K |
|
|
ADAM
2769
Adamas Trust
ADAM
$913M
| $499K | ﹤0.01% |
+20,045
| New | +$505K |
|
2770
Global Partners
GLP
$1.72B
| $498K | ﹤0.01% |
27,600
-18,009
| -39% | -$338K |
|
2771
Curis
CRIS
$3.91M
| $495K | ﹤0.01% |
131
-43
| -25% | -$180K |
|
2772
Lisata Therapeutics
LSTA
$10.6M
| $494K | ﹤0.01% |
7,083
+580
| +9% | +$41K |
|
|
BEL
2773
DELISTED
Belmond Ltd.
BEL
| $492K | ﹤0.01% |
37,000
-382,273
| -91% | -$4.79M |
|
|
PFIE
2774
DELISTED
Profire Energy, Inc
PFIE
| $490K | ﹤0.01% |
377,200
+35,740
| +10% | +$47.8K |
|
|
DPLO
2775
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $490K | ﹤0.01% |
33,100
+5,200
| +19% | +$86.7K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.